Cargando…

COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome

PURPOSE: [18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Dietz, Matthieu, Chironi, Gilles, Claessens, Yann-Erick, Farhad, Ryan Lukas, Rouquette, Isabelle, Serrano, Benjamin, Nataf, Valérie, Hugonnet, Florent, Paulmier, Benoît, Berthier, Frédéric, Keita-Perse, Olivia, Giammarile, Francesco, Perrin, Christophe, Faraggi, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382557/
https://www.ncbi.nlm.nih.gov/pubmed/32712702
http://dx.doi.org/10.1007/s00259-020-04968-8
_version_ 1783563266969042944
author Dietz, Matthieu
Chironi, Gilles
Claessens, Yann-Erick
Farhad, Ryan Lukas
Rouquette, Isabelle
Serrano, Benjamin
Nataf, Valérie
Hugonnet, Florent
Paulmier, Benoît
Berthier, Frédéric
Keita-Perse, Olivia
Giammarile, Francesco
Perrin, Christophe
Faraggi, Marc
author_facet Dietz, Matthieu
Chironi, Gilles
Claessens, Yann-Erick
Farhad, Ryan Lukas
Rouquette, Isabelle
Serrano, Benjamin
Nataf, Valérie
Hugonnet, Florent
Paulmier, Benoît
Berthier, Frédéric
Keita-Perse, Olivia
Giammarile, Francesco
Perrin, Christophe
Faraggi, Marc
author_sort Dietz, Matthieu
collection PubMed
description PURPOSE: [18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19. METHODS: Patients admitted with COVID-19 were prospectively enrolled. FDG PET/CT was performed from day 6 to day 14 of the onset of symptoms. Depending on FDG PET/CT findings, patients’ profiles were classified as “inflammatory” or “low inflammatory.” FDG PET/CT data were compared with chest CT evolution and short-term clinical outcome. All inflammatory sites were reported to screen potential extra-pulmonary tropism. RESULTS: Thirteen patients were included. Maximum standardized uptake values ranged from 4.7 to 16.3 in lungs. All patients demonstrated increased mediastinal lymph nodes glucose uptake. Three patients (23%) presented mild nasopharyngeal, two patients (15%) bone marrow, and five patients (38%) splenic mild increase in glucose uptake. No patient had significant digestive focal or segmental glucose uptake. There was no significant physiological myocardial glucose uptake in all patients except one. There was no correlation between PET lung inflammatory status and chest CT evolution or short-term clinical outcome. CONCLUSION: Inflammatory process at the presumed peak of the inflammatory phase in COVID-19 patients is obvious in FDG PET/CT scans. Glucose uptake is heterogeneous and typically focused on lungs. TRIAL REGISTRATION: NCT04441489. Registered 22 June 2020 (retrospectively registered). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-020-04968-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7382557
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-73825572020-07-28 COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome Dietz, Matthieu Chironi, Gilles Claessens, Yann-Erick Farhad, Ryan Lukas Rouquette, Isabelle Serrano, Benjamin Nataf, Valérie Hugonnet, Florent Paulmier, Benoît Berthier, Frédéric Keita-Perse, Olivia Giammarile, Francesco Perrin, Christophe Faraggi, Marc Eur J Nucl Med Mol Imaging Original Article PURPOSE: [18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19. METHODS: Patients admitted with COVID-19 were prospectively enrolled. FDG PET/CT was performed from day 6 to day 14 of the onset of symptoms. Depending on FDG PET/CT findings, patients’ profiles were classified as “inflammatory” or “low inflammatory.” FDG PET/CT data were compared with chest CT evolution and short-term clinical outcome. All inflammatory sites were reported to screen potential extra-pulmonary tropism. RESULTS: Thirteen patients were included. Maximum standardized uptake values ranged from 4.7 to 16.3 in lungs. All patients demonstrated increased mediastinal lymph nodes glucose uptake. Three patients (23%) presented mild nasopharyngeal, two patients (15%) bone marrow, and five patients (38%) splenic mild increase in glucose uptake. No patient had significant digestive focal or segmental glucose uptake. There was no significant physiological myocardial glucose uptake in all patients except one. There was no correlation between PET lung inflammatory status and chest CT evolution or short-term clinical outcome. CONCLUSION: Inflammatory process at the presumed peak of the inflammatory phase in COVID-19 patients is obvious in FDG PET/CT scans. Glucose uptake is heterogeneous and typically focused on lungs. TRIAL REGISTRATION: NCT04441489. Registered 22 June 2020 (retrospectively registered). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-020-04968-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-07-25 2021 /pmc/articles/PMC7382557/ /pubmed/32712702 http://dx.doi.org/10.1007/s00259-020-04968-8 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Dietz, Matthieu
Chironi, Gilles
Claessens, Yann-Erick
Farhad, Ryan Lukas
Rouquette, Isabelle
Serrano, Benjamin
Nataf, Valérie
Hugonnet, Florent
Paulmier, Benoît
Berthier, Frédéric
Keita-Perse, Olivia
Giammarile, Francesco
Perrin, Christophe
Faraggi, Marc
COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome
title COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome
title_full COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome
title_fullStr COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome
title_full_unstemmed COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome
title_short COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome
title_sort covid-19 pneumonia: relationship between inflammation assessed by whole-body fdg pet/ct and short-term clinical outcome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382557/
https://www.ncbi.nlm.nih.gov/pubmed/32712702
http://dx.doi.org/10.1007/s00259-020-04968-8
work_keys_str_mv AT dietzmatthieu covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT chironigilles covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT claessensyannerick covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT farhadryanlukas covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT rouquetteisabelle covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT serranobenjamin covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT natafvalerie covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT hugonnetflorent covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT paulmierbenoit covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT berthierfrederic covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT keitaperseolivia covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT giammarilefrancesco covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT perrinchristophe covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT faraggimarc covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome
AT covid19pneumoniarelationshipbetweeninflammationassessedbywholebodyfdgpetctandshorttermclinicaloutcome